Features
Excel add-in
New
PowerPoint add-in
New
Pricing
FAQ
Sign in
Sign up
Sign up
Low
Medium
High
Download PNG
Download SVG
Copy and edit
Revenue → Gross profit: $14.6B
Pharmaceutical → Revenue: $13.7B
Medical devices → Revenue: $7.7B
Revenue → Cost of revenue: $6.8B
Gross profit → SG&A: $5.8B
Oncology → Pharmaceutical: $4.6B
Immunology → Pharmaceutical: $4.6B
Gross profit → R&D: $4.5B
Gross profit → Operating profit: $4.2B
Operating profit → Net profit: $4.1B
Surgery → Medical devices: $2.5B
Orthopaedics → Medical devices: $2.3B
Neuroscience → Pharmaceutical: $1.8B
Interventional → Medical devices: $1.7B
Vision → Medical devices: $1.2B
Pulmonary → Pharmaceutical: $1.0B
Infectious diseases → Pharmaceutical: $0.9B
Other pharma → Pharmaceutical: $0.8B
Operating profit → Tax: $0.7B
Other → Operating profit: $0.4B
Interest → Operating profit: $0.2B
Gross profit → In-process R&D: $0.1B
Gross profit → Restructuring: $0.1B
Immunology: $4.6B
Pharmaceutical: $13.7B
Infectious diseases: $0.9B
Neuroscience: $1.8B
Oncology: $4.6B
Pulmonary: $1.0B
Other pharma: $0.8B
Revenue: $21.4B
Medical devices: $7.7B
Interventional: $1.7B
Orthopaedics: $2.3B
Surgery: $2.5B
Vision: $1.2B
Gross profit: $14.6B
Cost of revenue: $6.8B
Operating profit: $4.8B
SG&A: $5.8B
R&D: $4.5B
In-process R&D: $0.1B
Restructuring: $0.1B
Net profit: $4.1B
Interest: $0.2B
Other: $0.4B
Tax: $0.7B
created with SankeyArt.com
Immunology
$4.6B
Pharmaceutical
$13.7B
4% Y/Y
Infectious diseases
$0.9B
Neuroscience
$1.8B
Oncology
$4.6B
Pulmonary
$1.0B
Other pharma
$0.8B
Revenue
$21.4B
7% Y/Y
Medical devices
$7.7B
13% Y/Y
Interventional
$1.7B
Orthopaedics
$2.3B
Surgery
$2.5B
Vision
$1.2B
Gross profit
$14.6B
5% Y/Y
Cost of revenue
$6.8B
12% Y/Y
Operating profit
$4.8B
5% Y/Y
SG&A
$5.8B
9% Y/Y
R&D
$4.5B
21% Y/Y
In-process R&D
$0.1B
-66% Y/Y
Restructuring
$0.1B
Net profit
$4.1B
28% Y/Y
Interest
$0.2B
-72% Y/Y
Other
$0.4B
Tax
$0.7B
13% Y/Y
Johnson & Johnson Q4 FY23 Income Statement
2022
Q4
Full Year
2023
Q1
Q2
Q3
Q4
Full Year
2024
Q1
Q2
Q3
